SCHEMBL5726353

SCHEMBL5726353

CNS(=O)(=O)c1ccc(Nc2nc(N)n(C(=O)c3c(F)ccc(C)c3F)n2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 14/20 0.68
▸ CDK2 P24941 9/20 0.68
▸ CCNB2 O95067 7/20 0.68
▸ CCNB1 P14635 7/20 0.68
▸ CCNB3 Q8WWL7 7/20 0.68
▸ CDK4 P11802 2/20 0.68
▸ CCNA2 P20248 2/20 0.68
▸ FGFR2 P21802 2/20 0.68
▸ CCND1 P24385 2/20 0.68
▸ MAPK3 P27361 2/20 0.68
▸ MAPK1 P28482 2/20 0.68
▸ KDR P35968 2/20 0.68
▸ GSK3A P49840 2/20 0.68
▸ GSK3B P49841 2/20 0.68
▸ CCNA1 P78396 2/20 0.68
▸ EGFR P00533 1/20 0.68
▸ INSR P06213 1/20 0.68
▸ JAK1 P23458 6/20 0.63
▸ TYK2 P29597 6/20 0.63
▸ JAK2 O60674 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726498 0.90 CDK1 (0.71) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5727292 0.90 CDK1 (0.83) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL7092328 0.89 CDK1 (0.78) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5726923 0.88 CDK1 (0.67) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5964771 0.86 CDK1 (0.65) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5964702 0.86 CDK1 (0.82) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5725430 0.82 CDK1 (0.84) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5964639 0.82 CDK1 (0.59) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5726856 0.81 CDK1 (0.74) CDK1CDK2CCNB2CCNB1CCNB3
SCHEMBL5727451 0.80 CDK1 (0.80) CDK1CDK2CCNB2CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355889-B1 SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS ORTHO MCNEIL PHARM INC (US) 2006-06-07 — — EP claimed
US-6924302-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2005-08-02 — — US claimed
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-04-22 — — US claimed
EP-1712550-A2 Substituted triazole diamine derivatives as kinase inhibitors Ortho-McNeil Pharmaceutical, Inc. (US) 2006-10-18 — — EP disclosed
EP-1355889-B1 SUBSTITUTED TRIAZOLE DIAMINE DERIVATIVES AS KINASE INHIBITORS ORTHO MCNEIL PHARM INC (US) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors MAP2K2, PRKDC, MAP2K3 CDK1 387/4885CDK2 344/4885CCNB2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback